IL173301A0 - Bioactive compositions comprising triazines - Google Patents

Bioactive compositions comprising triazines

Info

Publication number
IL173301A0
IL173301A0 IL173301A IL17330106A IL173301A0 IL 173301 A0 IL173301 A0 IL 173301A0 IL 173301 A IL173301 A IL 173301A IL 17330106 A IL17330106 A IL 17330106A IL 173301 A0 IL173301 A0 IL 173301A0
Authority
IL
Israel
Prior art keywords
triazines
bioactive compositions
bioactive
compositions
Prior art date
Application number
IL173301A
Other languages
English (en)
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Publication of IL173301A0 publication Critical patent/IL173301A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL173301A 2003-07-31 2006-01-23 Bioactive compositions comprising triazines IL173301A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49163103P 2003-07-31 2003-07-31
US49163803P 2003-07-31 2003-07-31
PCT/US2004/024515 WO2005011629A1 (en) 2003-07-31 2004-07-29 Bioactive compositions comprising triazines

Publications (1)

Publication Number Publication Date
IL173301A0 true IL173301A0 (en) 2006-06-11

Family

ID=34118876

Family Applications (2)

Application Number Title Priority Date Filing Date
IL173301A IL173301A0 (en) 2003-07-31 2006-01-23 Bioactive compositions comprising triazines
IL173300A IL173300A0 (en) 2003-07-31 2006-01-23 Compositions for encapsulation and controlled release

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL173300A IL173300A0 (en) 2003-07-31 2006-01-23 Compositions for encapsulation and controlled release

Country Status (11)

Country Link
US (2) US20080063714A1 (enExample)
EP (2) EP1651185A1 (enExample)
JP (2) JP2007500713A (enExample)
KR (2) KR20060054371A (enExample)
AU (2) AU2004261243A1 (enExample)
BR (2) BRPI0413143A (enExample)
CA (2) CA2534042A1 (enExample)
IL (2) IL173301A0 (enExample)
MX (2) MXPA06001054A (enExample)
RU (2) RU2006102188A (enExample)
WO (2) WO2005012488A2 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
EP1658076B1 (en) * 2003-08-27 2013-03-06 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted imidazoquinolines
ES2544477T3 (es) 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
KR20060120069A (ko) 2003-10-03 2006-11-24 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피라졸로피리딘 및 그의 유사체
RU2409576C2 (ru) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US7687115B2 (en) 2004-11-24 2010-03-30 3M Innovative Properties Company Method for making nanostructured surfaces
US7247723B2 (en) 2004-11-24 2007-07-24 3M Innovative Properties Company Metallic chromonic compounds
US7582330B2 (en) 2004-11-24 2009-09-01 3M Innovative Properties Counsel Method for making metallic nanostructures
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
CA2592904C (en) * 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
JP2008530252A (ja) 2005-02-09 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド オキシムおよびヒドロキシルアミンで置換されたチアゾロ［４，５−ｃ］環化合物ならびに方法
WO2006086449A2 (en) 2005-02-09 2006-08-17 Coley Pharmaceutical Group, Inc. Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006091394A2 (en) * 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
WO2006098852A2 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
EP1851220A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazonaphthyridines
JP2008538203A (ja) * 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド インターフェロンの生合成を優先的に誘導する方法
EP1851218A2 (en) * 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2601067A1 (en) 2005-05-04 2006-11-09 Medigene Ag Method of administering a cationic liposomal preparation comprising paclitaxel
EA200800782A1 (ru) * 2005-09-09 2008-08-29 Коли Фармасьютикал Груп, Инк. ПРОИЗВОДНЫЕ АМИДА И КАРБАМАТА N-{2-[4-АМИНО-2-(ЭТОКСИМЕТИЛ)-1Н-ИМИДАЗОЛО[4,5-c]ХИНОЛИН-1-IL]-1,1-ДИМЕТИЛЭТИЛ}МЕТАНСУЛЬФОНАМИДА И СПОСОБЫ
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US7629027B2 (en) 2005-10-14 2009-12-08 3M Innovative Properties Company Method for making chromonic nanoparticles
US7718716B2 (en) 2005-10-14 2010-05-18 3M Innovative Properties Company Chromonic nanoparticles containing bioactive compounds
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
US7807661B2 (en) * 2005-12-08 2010-10-05 3M Innovative Properties Company Silver ion releasing articles and methods of manufacture
US8092710B2 (en) 2005-12-19 2012-01-10 3M Innovative Properties Company Hierarchical chromonic structures
US7601769B2 (en) 2005-12-19 2009-10-13 3M Innovative Peroperties Company Multilayered chromonic structures
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
US7824732B2 (en) 2005-12-28 2010-11-02 3M Innovative Properties Company Encapsulated chromonic particles
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
US8329721B2 (en) * 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
BRPI0709075A2 (pt) * 2006-03-20 2011-10-11 Medigene Ag tratamento de cáncer de mama triplo receptor negativo
US20070243258A1 (en) * 2006-04-13 2007-10-18 3M Innovative Properties Company Method and apparatus for forming crosslinked chromonic nanoparticles
US20070275185A1 (en) * 2006-05-23 2007-11-29 3M Innovative Properties Company Method of making ordered nanostructured layers
WO2008030511A2 (en) * 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
US20100028420A1 (en) * 2006-12-22 2010-02-04 3M Innovative Properties Company Controlled release composition and process
WO2009139939A2 (en) * 2008-02-22 2009-11-19 The University Of North Carolina At Chapel Hill Hybrid nanoparticles as anti-cancer therapeutic agents and dual therapeutic/imaging contrast agents
PL2395843T3 (pl) 2009-02-13 2018-01-31 Monsanto Technology Llc Kapsułkowanie herbicydów do zmniejszenia uszkodzeń upraw
WO2010129728A2 (en) * 2009-05-06 2010-11-11 3M Innovative Properties Company Articles with shell structures including a cell extractant and biodetection methods thereof
HRP20170433T1 (hr) 2010-08-17 2017-05-05 3M Innovative Properties Company Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
AR082855A1 (es) * 2010-08-18 2013-01-16 Monsanto Technology Llc Aplicacion temprana de acetamidas encapsuladas para reducir daños en los cultivos
CN103582496B (zh) 2011-06-03 2016-05-11 3M创新有限公司 具有聚乙二醇链段的异双官能连接基以及由其制成的免疫应答调节剂缀合物
WO2012167081A1 (en) 2011-06-03 2012-12-06 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
JP6049712B2 (ja) 2011-07-08 2016-12-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 抗癌治療及び画像化並びに骨障害治療のための金属ビスホスホネートナノ粒子
WO2015069926A1 (en) 2013-11-06 2015-05-14 The University Of Chicago Nanoscale carriers for the delivery or co-delivery of chemotherapeutics, nucleic acids and photosensitizers
BR112016016650B1 (pt) 2014-01-27 2021-04-13 Monsanto Technology Llc Composições de concentrados de herbicidas aquosos
US10806694B2 (en) 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
EP3206987B2 (en) 2014-10-14 2024-07-24 The University of Chicago Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
EP3291838A4 (en) * 2015-05-05 2019-01-02 B.G. Negev Technologies and Applications Ltd. Anionic nanoparticles for use in the delivery of anionic small molecule drugs
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
CA3066746A1 (en) 2017-06-13 2018-12-20 Monsanto Technology Llc Microencapsulated herbicides
CN111194232B (zh) 2017-08-02 2023-01-31 芝加哥大学 纳米级金属有机层和金属有机纳米片
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
WO2020160223A1 (en) 2019-01-30 2020-08-06 Monsanto Technology Llc Microencapsulated acetamide herbicides

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2512572A (en) * 1950-06-20 Substituted pteridines and method
US4030812A (en) * 1975-06-16 1977-06-21 Minnesota Mining And Manufacturing Company Lyotropic birefringent films
US4031092A (en) * 1975-06-16 1977-06-21 Minnesota Mining And Manufacturing Company 1,3-Bis-(carboxy-phenylamino)-s-triazines
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5756747A (en) * 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US5037986A (en) * 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US4988815A (en) * 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
ATE121088T1 (de) * 1990-10-05 1995-04-15 Minnesota Mining & Mfg Verfahren zur herstellung von imidazo(4,5- c>chinolin-4-aminen.
US5175296A (en) * 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
DE4211475A1 (de) * 1991-12-14 1993-06-17 Asta Medica Ag Pulverinhalator
US5352461A (en) * 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
IL105325A (en) * 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
CA2167042A1 (en) * 1993-07-15 1995-01-26 Kyle J. Lindstrom Imidazo[4,5-c]pyridin-4-amines
CA2166970C (en) * 1993-07-15 2000-12-19 Oh-Seung Kwon Seals for use in an aerosol delivery device
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5741908A (en) * 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) * 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
WO1998001448A1 (en) * 1996-07-03 1998-01-15 Japan Energy Corporation Novel purine derivatives
US6387938B1 (en) * 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
CZ294563B6 (cs) * 1996-10-25 2005-02-16 Minnesota Mining And Manufacturing Company Sloučeniny představující modifikátory imunitní odezvy při léčení nemocí mediovaných TH2 buňkami a nemocí odvozených
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
US6069149A (en) * 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6248364B1 (en) * 1997-04-07 2001-06-19 3M Innovative Properties Company Encapsulation process and encapsulated products
US6426334B1 (en) * 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
DE69838294T2 (de) * 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
US5948487A (en) * 1997-09-05 1999-09-07 3M Innovative Properties Company Anisotropic retardation layers for display devices
CA2311742C (en) * 1997-11-28 2009-06-16 Sumitomo Pharmaceuticals Co., Ltd. 6-amino-9-benzyl-8-hydroxypurine derivatives
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
TW572758B (en) * 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US6214499B1 (en) * 1998-09-11 2001-04-10 Eastman Kodak Company Liquid crystalline filter dyes for imaging elements
US6180295B1 (en) * 1998-09-11 2001-01-30 Eastman Kodak Company Liquid crystalline filter dyes for imaging elements
US6245399B1 (en) * 1998-10-14 2001-06-12 3M Innovative Properties Company Guest-host polarizers
SK287112B6 (sk) * 1999-01-08 2009-12-07 3M Innovative Properties Company Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6451810B1 (en) * 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6338443B1 (en) * 1999-06-18 2002-01-15 Mercury Enterprises, Inc. High efficiency medical nebulizer
WO2001012804A2 (en) * 1999-08-13 2001-02-22 Hybridon, Inc. MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
US6574044B1 (en) * 1999-10-25 2003-06-03 3M Innovative Properties Company Polarizer constructions and display devices exhibiting unique color effects
US6538714B1 (en) * 1999-10-25 2003-03-25 3M Innovative Properties Company Dual color guest-host polarizers and devices containing guest-host polarizers
US6376669B1 (en) * 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
JP2003534563A (ja) * 1999-11-12 2003-11-18 スリーエム イノベイティブ プロパティズ カンパニー 液晶配向構造体およびそれを含む光学装置
DE10036282A1 (de) * 2000-07-26 2002-02-07 Bosch Gmbh Robert Verfahren und Vorrichtung zur Steuerung einer Antriebseinheit
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
US6488866B1 (en) * 2000-11-08 2002-12-03 3M Innovative Properties Company Liquid crystal materials and alignment structures and optical devices containing same
US6525064B1 (en) * 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6545017B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6411354B1 (en) * 2001-05-11 2002-06-25 Kent State University Bulk alignment of lyotropic chromonic liquid crystals
US6673398B2 (en) * 2001-05-14 2004-01-06 Kent State University Alignment of lyotropic chromonic liquid crystals at surfaces as monolayers and multilayered stacks
UA79764C2 (en) * 2001-11-27 2007-07-25 Anadys Pharmaceuticals Inc 3-?-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF

Also Published As

Publication number Publication date
US20080063714A1 (en) 2008-03-13
KR20060054371A (ko) 2006-05-22
AU2004261243A1 (en) 2005-02-10
EP1651035A2 (en) 2006-05-03
MXPA06001004A (es) 2006-04-27
JP2007500712A (ja) 2007-01-18
CA2533128A1 (en) 2005-02-10
BRPI0413143A (pt) 2006-10-03
BRPI0413164A (pt) 2006-10-03
AU2004261987A1 (en) 2005-02-10
US20080039533A1 (en) 2008-02-14
RU2006102187A (ru) 2006-08-10
RU2006102188A (ru) 2006-07-10
EP1651185A1 (en) 2006-05-03
IL173300A0 (en) 2006-06-11
MXPA06001054A (es) 2006-04-24
WO2005012488A2 (en) 2005-02-10
WO2005011629A1 (en) 2005-02-10
KR20060056354A (ko) 2006-05-24
CA2534042A1 (en) 2005-02-10
JP2007500713A (ja) 2007-01-18
WO2005012488A3 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
IL173301A0 (en) Bioactive compositions comprising triazines
EP1560556A4 (en) ANTIMICROBIAL COMPOSITIONS
EP1902724A3 (en) Antimicrobial compositions
GB0212062D0 (en) Jetable compositions
IL165372A0 (en) Immunodenic compositions
PL377411A1 (pl) Kompozycje prebiotyczne
GB0224415D0 (en) Compositions
EP1814591A4 (en) BIOACTIVE PREPARATIONS
GB0208609D0 (en) Compositions
IL171942A0 (en) Compositions containing ecteinascidin-743
GB0329907D0 (en) Compositions
GB0221894D0 (en) Compositions
EP1613352A4 (en) MICRO-AGREED COMPOSITIONS
AU2003269904A8 (en) Antigen-polymer compositions
GB0222259D0 (en) Antimicrobial compositions
GB0203395D0 (en) Compositions
GB0329597D0 (en) Compositions
GB2406053B (en) Antimicrobial composition
GB0203396D0 (en) Compositions
GB0328845D0 (en) Antimicrobial composition
EP1708735A4 (en) ANTIMICROBIAL COMPOSITION
GB0300602D0 (en) Compositions
GB0317524D0 (en) Compositions
GB0324574D0 (en) Novel compositions
GB0328023D0 (en) Novel compositions